Solid Tumors, Adult Clinical Trial
Official title:
The Efficacy and Safety of Tumor Treatment Vaccine in Patients With Advanced Solid Tumors
This is a study of the clinical efficacy and mechanism study of tumor treatment vaccine (TTV, also known as Neo-BCV) in patients with recurrent and refractory advanced solid tumors.
The study aims to explore the safety and effectiveness of Neo-BCV in the treatment of advanced solid tumors.The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04467853 -
A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT05698888 -
Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04587479 -
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT05472220 -
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05354323 -
NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05430373 -
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04739293 -
Study of ON 123300 in Patients With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT05887492 -
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05228015 -
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT05018273 -
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04621435 -
Imaging of Solid Tumors Using FAP-2286
|
Phase 1 | |
| Recruiting |
NCT05861895 -
A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06088472 -
TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors
|
Early Phase 1 | |
| Recruiting |
NCT05768139 -
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 |